Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now

You can switch off notifications anytime using browser settings.
Stock Analysis, IPO, Mutual Funds, Bonds & More

Price erosion symptoms: Dr Reddy's Laboratories plans to launch value-added drugs in US

Dr Reddy's Laboratories has said the company plans to launch several value-added products this fiscal tooffset the persisting problem.

Jul 07, 2019, 03.12 PM IST
Maintaining that pricing pressure will continue in the US market, Dr Reddy's Laboratories has said the company plans to launch several value-added products this fiscal tooffset the persisting problem.

As part of the diversification and new market entry strategy, DRL plans to re-focus some of its Research and Development resources to service the high potential branded generics markets such as China, Russia and other emerging markets.

"We believe that pricing pressures will continue to affect all players in generics in the US. Overcoming this necessitates a robust pipeline of complex formulations with limited competition a pipeline that allows your company to introduce several value-added products each year, and thus make up for price erosions on the earlier launched products," K Satish Reddy and GV Prasad, chairman and co-chairman respectively said in the latest annual report.

As many as 110 generic filings awaiting approval from the USFDA and the company has to leverage this and ensure that they succeed in delivering these products, molecule by molecule, to the US on the due dates, they said.

"Given the challenges in the US market, we will continue our efforts to diversify our market presence," they said.

The drug maker said it will continue to focus on complex formulations primarily injectables and oral solid dosage forms as well as OTC brands in the medium term, and controlled substances under class II, and non-substitutable generics in the longer term, the report indicated with respect to North America generics.

Despite concerns about a trade war between the US and China, it is not a surprise that China is still viewed as a huge market opportunity for the pharmaceutical industry, the report said.

"We have also grown well in China and expect it to be a relatively high growth market in the next few years," it said.

The strategy for growth in emerging markets is to continue improving the company's market share in chosen therapy areas, including expansion of biosimilars and the oncology portfolio.

"We will focus on scaling up in our major markets, which include Russia, China, Brazil, South Africa and Ukraine," it said.

The report further said the pharma major will attempt to further strengthen its presence presence in six chosen spaces-United States, India, Russia, China, Global Hospitals including Biosimilars, and the Global API (Active Pharmaceutical Ingredients) business- to drive next level of growth.

"Our target is to attain self-sustainability for each of our business. Despite multiple headwinds being faced by the overall industry, we are cautiously optimistic of improving our performance in FY2020 by calibrating our levers which would suit the business environment better and, thus, guide us to better performance for the year ahead," DRL said.

Also Read

Buy Dr. Reddy's Laboratories, target Rs 2780: Kunal Bothra

Sell Dr. Reddy's Laboratories, target Rs 2,480: Kunal Bothra

Reduce Dr. Reddy's Laboratories, target Rs 2,759: Elara Capital

Buy Dr. Reddy's Laboratories, target Rs 3,000: Manas Jaiswal

Buy Dr. Reddy's Laboratories, target Rs 2,838: Jay Thakkar

Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.

Other useful Links

Follow us on

Download et app

Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service